Welcome to our dedicated page for Enzo Biochem news (Ticker: ENZB), a resource for investors and traders seeking the latest updates and insights on Enzo Biochem stock.
Enzo Biochem, Inc. reports company developments tied to material agreements, shareholder voting matters, capital-structure disclosures, governance, risk factors, and operating and financial results. ENZB news centers on corporate updates for an operating company.
Enzo Biochem (OTCQX: ENZB) has announced its acquisition by Battery Ventures in an all-cash transaction valued at approximately $37 million. Under the agreement, Battery will acquire Enzo for $0.70 per share, representing a 75% premium to the company's closing price on April 22, 2025, and a 32% premium to the June 23, 2025 closing price.
The transaction, expected to close in Q3 2025, follows a comprehensive strategic review by the company's Special Committee. Upon completion, Enzo will become privately held and delist from public markets. The company's officers, directors, and largest shareholder have agreed to vote in favor of the transaction.